Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.

You may also be interested in...

Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe

Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.

Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio

The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.

Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer

The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts